Antisoma Buys Oncology Firm Xanthus
Through deal, Antisoma acquires Xanafide in Phase III for secondary AML and oral fludarabine, awaiting FDA approval.
Through deal, Antisoma acquires Xanafide in Phase III for secondary AML and oral fludarabine, awaiting FDA approval.